Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability

BACKGROUND: Solid tumors pose unique roadblocks to treatment with chimeric antigen receptor (CAR) T cells, including limited T-cell persistence, inefficient tumor infiltration, and an immunosuppressive tumor microenvironment. To date, attempts to overcome these roadblocks have been unsatisfactory. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jianghui, Sheng, Jianpeng, Zhang, Qi, Ji, Yongtao, Wang, Xun, Zhang, Junlei, Wu, Jiangchao, Song, Jinyuan, Bai, Xueli, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972435/
https://www.ncbi.nlm.nih.gov/pubmed/36849200
http://dx.doi.org/10.1136/jitc-2022-006119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972435/
https://www.ncbi.nlm.nih.gov/pubmed/36849200
http://dx.doi.org/10.1136/jitc-2022-006119

Ejemplares similares